| dc.contributor |
Médecins Sans Frontières, Geneva University Hospitals, Geneva, Switzerland. francois.chappuis@hcuge.ch |
|
| dc.creator |
Chappuis, F |
|
| dc.creator |
Udayraj, N |
|
| dc.creator |
Stietenroth, K |
|
| dc.creator |
Meussen, A |
|
| dc.creator |
Bovier, P A |
|
| dc.date |
2005-09-01 |
|
| dc.date.accessioned |
2017-01-31T07:09:19Z |
|
| dc.date.available |
2017-01-31T07:09:19Z |
|
| dc.identifier |
Eflornithine is Safer Than Melarsoprol for the Treatment of Second-Stage Trypanosoma Brucei Gambiense Human African Trypanosomiasis. 2005, 41 (5):748-51 Clin. Infect. Dis. |
|
| dc.identifier |
1537-6591 |
|
| dc.identifier |
16080099 |
|
| dc.identifier |
10.1086/432576 |
|
| dc.identifier |
http://hdl.handle.net/10144/17284 |
|
| dc.identifier |
http://fieldresearch.msf.org/msf/handle/10144/17284 |
|
| dc.identifier |
Clinical Infectious Diseases |
|
| dc.identifier.uri |
http://dspace.mediu.edu.my:8181/xmlui/handle/10144/17284 |
|
| dc.description |
Patients with second-stage human African trypanosomiasis treated with eflornithine (n = 251) in 2003 in Kiri, southern Sudan, had an adjusted relative risk of death of 0.2 and experienced significantly fewer cutaneous and neurological adverse effects than did patients who were treated with melarsoprol in 2001 and 2002 (n = 708). |
|
| dc.language |
en |
|
| dc.publisher |
Published by: Infectious Diseases Society of America |
|
| dc.relation |
http://www.journals.uchicago.edu/page/cid/brief.html |
|
| dc.rights |
Archived on this site with permission and copyright by the Infectious Diseases Society of America |
|
| dc.title |
Eflornithine is Safer Than Melarsoprol for the Treatment of Second-Stage Trypanosoma Brucei Gambiense Human African Trypanosomiasis. |
|